Faster Seizure Detection. Better Care Decisions.

Used in more than 550 hospitals,* Ceribell delivers proven clinical and financial impact across emergency and critical care settings

The Cost of Missed Seizures in Critical Care

Non-Convulsive Seizures Are Highly Prevalent and Often Undiagnosed
in Critical Patients1

Why Time to EEG Matters

Treatment Response Rate7

Time in Seizure is Associated with Increase in Mortality8

Ceribell:
Your 24/7 Continuous Bedside EEG Monitoring Solution

Ceribell® Indications, Safety & Warnings

Real-World Impact, Reported in 22,000 Provider Surveys

Surveys collected from 1/13/2024 to 8/5/2025

Provider-reported surveys reveal how Ceribell POC EEG may inform care at the bedside.

The Impact

Estimated Savings Across 459 Hospitals

$52.6 Million

saved from reduced ASMs**
saved from avoided intubations
saved from avoided ICU admissions
saved from avoided transfers

See the results of a one-year analysis of survey data:

Download the White Paper

The Evidence

The Evidence Supports Ceribell’s Economic Value

Study: Review of 12 peer-reviewed studies confirms Ceribell helps refine clinical decisions, reduce resource use, and improve hospital margins.17

 

 

 

Read Study

Multi-center retrospective analysis13 in ICU patients shows that initial evaluation with Ceribell vs. conventional EEG is associated with:

shorter median ICU
length of stay with Ceribell vs. conventional EEG
more patients from the Ceribell cohort had better neurological outcomes†
faster door-to-EEG time with the Ceribell System; 5.9 hours with Ceribell vs. 25.3 hours with conventional EEG

A Financially Sound EEG Strategy

Ceribell works with your existing reimbursement structure—and adds more opportunities to recoup operational costs.

Value Drivers

  • Existing CPT codes18
  • Reduce patient transfers15,16
  • Potential CC/MCC and DRG coverage following seizure diagnosis19
  • Potential NTAP payments12

Cost Savings

  • Fewer medications20,22
  • Shorter hospital and ICU length of stay13,19
  • Fewer EEG tech overtime costs23
  • Avoid unnecessary ICU admissions24

Economic Impact in Action: One Hospital’s Experience

90-day Reimbursement Review – Case Study Example††

  • 86-bed Midwest hospital with 10-11 uses of the Ceribell system per month
  • Standalone hospital with single billing/coding department

10 out of 33 (30%) claims with the Ceribell NTAP code were paid at a total of $8,650

Appropriately billed for technical and professional codes‡

1 recorded case with MCC payment rate based on seizure diagnosis from use of Ceribell

​

Ceribell: Your Partner in Building a POC EEG Program

Discover the Ceribell Advantage

Ceribell for the ICUCeribell Pointer Icon

Ceribell for the EDCeribell Pointer Icon

Ceribell for NeurologyCeribell Pointer Icon

decorative

Resources

featured resources orange dot

Health Economics and Staffing Webinar: Expanding Care with Ceribell Rapid EEG Improves Staff Satisfaction and Finances

Watch Our Webinar

Webinar

featured resources orange dot

Ceribell Health Economics Manuscript: Use of Ceribell EEG results in average savings of >$5k per patient

Read More

In The News

featured resources orange dot

Health Economics and Staffing Webinar: Stopping unnecessary patient transfers: How a Point-of-Care EEG impacted our transfers and bottom line

Watch Our Webinar

Webinar

References and Citations


1. Herman, S.T., et al. (2015) J Clin Neurophysiol. 32(2):87-95  
2. Limotai, C., et al. (2019) Crit Care Med. 47(4):e366-e373   
3. Laccheo, I., et al. (2015) Neurocrit Care. 22:202-211
4. De Marchis, G.M., et al. (2016) Neurology. 86(3):253-260
5. Claassen, J., et al. (2004). Neurology. 62(10):1743–1748
6. Rudin, D., et al. (2011) Epilepsy Res. 96(1-2):140-50
7. Lowenstein, D.H., et al. (1993) Neurology, 43(3 Pt 1):483-488
8. Young, G.B., et al. (1996). Neurology, 47(1):83-89   
9. Vespa, P.M., et al. (2020) Crit Care Med. 48(9):1249-1257
10. FDA 510k Clearance Letter K241589
11. Karunakaran, S., et al., (2024). AES Annual Meeting Poster
12. CMS FY 2024 IPPS Final Rule. CMS-1785-F, 88 Fed. Reg. 58927-58930, Aug. 28, 2023​
13. Desai, M., et al. (2025) Neurocrit Care. 42(1):108-117
14. Eberhard, E., et al. (2023) J Neurosci Nurs.
15. Madill, E.S., et al. (2022) Epileptic Disorders. 24(3):507-516
16. Ward, J., et al. (2023) Front. Digit. Health. 5(1)
17. Green, A., et al. (2024). J Med Econ. 27(1):51-61
18. AMA CPT 2024 Professional Edition. CMS 2024 Physician Fee Schedule
19. Eberhard, E., et al. (2023) J Neurosci Nurs. 55(5):157-163
20. Ney, J.P., et al. (2021) J Med Econ. 24(1):318-327


21. Kurup, D., et al. (2022) Epileptic Disorders. 24(5): 1-7
22. Kozak, R., et al. (2023). JACEP Open. 4(4). 
23. HCA Internal analysis. Data available upon request
24. Ceribell, Inc. (2025) [White Paper] The Impact of Ceribell at the Bedside.

* As of July 2025
** NPV = Negative Predictive Value, ASM = Anti-Seizure Medication
† Using modified Rankin Scale score (mRS) greater than or equal to 4 at discharge as an indicator of functional disability
†† Case study is a representative of real medical events
‡ Hospital employs physicians and collects professional fees

※ For informational and illustrative purposes only. Patient care decisions must be made solely by licensed health care professionals. This is not legal or financial advice and not intended to increase or maximize reimbursement. Hospitals and providers are solely responsible for compliance with Medicare and other payer policies. Information provided does not represent the reimbursement of any individual facility – results may vary. Ceribell does not guarantee reimbursement, MS-DRG payment, NTAP eligibility or coverage for the diagnosis of ESE. For guidance on coding, coverage and payment policies, consult your Medicare Contractor, reimbursement specialists, and/or legal counsel.